Radiofrequency ablation (RFA), especially percutaneous RFA (PRFA), is a novel technique for the treatment of hepatocellular carcinoma (HCC) that is becoming in
Androgen insensitivity syndrome (AIS) was first described by the American gynecologist Morris in 1953 and was initially described in 82 patients.1 The syndrome